自体纯化CD34^+细胞移植治疗中/高危淋巴细胞来源恶性肿瘤的临床研究  

Purified autologous CD34^+ cell transplantation for the treatment of Medium/High Risk lymphocytic malignancies

作　　者：曾韫璟[1] 高力[1] 陈幸华[1] 张曦[1] 高蕾[1] 张诚[1] 文钦[1] 孔佩艳[1] 刘红[1] 彭贤贵[1] 

机构地区：[1]第三军医大学新桥医院血液科全军血液病中心,重庆400037

出　　处：《中国输血杂志》2012年第2期120-122,共3页Chinese Journal of Blood Transfusion

基　　金：国家自然科学基金(81070388);重庆市自然科学基金重点项目(2009BA5056);第三军医大学临床科研基金(2010D249)

摘　　要：目的分析自体纯化CD34+细胞移植治疗中/高危淋巴细胞来源恶性肿瘤的临床疗效。方法 10名中/高危组淋巴细胞来源恶性肿瘤患者行自体纯化CD34+细胞移植治疗,细胞分选采用cliniMACS系统。计算并统计分选纯度和CD34+细胞回收率,观察移植相关并发症及患者生存情况。结果纯化后CD34+细胞纯度为(87.79±3.73)%,回收率达到(65.74±10.37)%。10名患者全部顺利造血重建,感染发生率50%(5/10例),复发率为20%(2/10例)。结论利用CliniMACS系统进行外周血CD34+细胞分选,CD34+细胞纯度、回收率均满意,自体移植后造血功能重建顺利,近期疗效满意。Objective To study the effectiveness of CD34＋ selected autologous peripheral blood stem cell transplantation（APBSCT） in medium/high risk lymphocytic malignancies.Methods 10 patients received autologous CD34＋ selected APBSCT,purified by CliniMACS device.The sorting purity and recovery of CD34＋ cells were calculated.Transplant-related complications and prognosis were observed.Results After selection,the mean recovery of CD34＋ cells was（65.74±10.37）% and the mean purity was（87.79±3.73）%.All 10 patients achieved hematopoietic recovery successfully.The rates of infectiou and relapse were 50%（5/10）,and 20%（2/10）,respectively.Conclusion Peripheral blood CD34＋ selection and purification using CliniMACS system are effective with satisfactory purity and recovery.Hemopoietic recovery can be achieved with good short term effectiveness.

关 键 词：CD34+细胞 自体 移植 肿瘤 临床疗效 

分 类 号：R318.06[医药卫生—生物医学工程]